Hypoxic indices for obstructive sleep apnoea severity and cardiovascular disease risk prediction: A comparison and application in a community population
Respirology · 2024
DOI: 10.1111/resp.14754 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Respirology, 2024. Verfasst von Xinjie Hui und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medic…. Hauptthemen laut MEDLINE: Sleep Apnea, Obstructive, Cardiovascular Diseases, Hypoxia, Severity of Illness Index. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Key Research and Development Program of China, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Background and Objective The apnoea‐hypopnoea index (AHI) and oxygen desaturation index (ODI) encounter challenges in capturing the intricate relationship between obstructive sleep apnoea (OSA) and cardiovascular disease (CVD) risks. Although novel hypoxic indices have been proposed to tackle these limitations, there remains a gap in comprehensive validation and comparisons across a unified dataset.
Methods
Samples were derived from the Sleep Heart Health Study (SHHS), involving 4485 participants aged over 40 years after data quality screening. The study compared several key indices, including AHI, ODI, the reconstructed hypoxic burden (rHB), the percentage of sleep time with the duration of respiratory events causing desaturation (pRED_3p) and the sleep breathing impairment index (SBII), in relation to CVD mortality and morbidity risks. Adjusted Cox proportional models were employed to calculate hazard ratios (HRs) for each index, and comparisons were performed.
Results
SBII and pRED_3p exhibited significant correlations with both CVD mortality and morbidity, with SBII showing the highest adjusted HR (95% confidence interval) for mortality (2.04 [1.25, 3.34]) and pRED_3p for morbidity (1.43 [1.09‐1.88]). In contrast, rHB was only significant in predicting CVD mortality (1.63 [1.05–2.53]), while AHI and ODI did not show significant correlations with CVD outcomes. The adjusted models based on SBII and pRED_3p exhibited optimal performance in the CVD mortality and morbidity datasets, respectively.
Conclusion
This study identified the optimal indices for OSA‐related CVD risks prediction, SBII for mortality and pRED_3p for morbidity. The open‐source online platform provides the computation of the indices.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- State Key Laboratory of Information Photonics and Optical Communications, Beijing University of Posts and Telecommunications, Beijing, China.
ORCID-Profile: Xinjie Hui, Zeyu Xu, Yi Xiao
Förderung
- NHLBI NIH HHS
- National Key Research and Development Program of China
- National Heart, Lung, and Blood Institute
Zitieren
APA
Hui, X., Cao, W., Xu, Z., Guo, J., Luo, J., & Xiao, Y. (2024). Hypoxic indices for obstructive sleep apnoea severity and cardiovascular disease risk prediction: A comparison and application in a community population. Respirology. https://doi.org/10.1111/resp.14754
Vancouver
Hui X, Cao W, Xu Z, Guo J, Luo J, Xiao Y. Hypoxic indices for obstructive sleep apnoea severity and cardiovascular disease risk prediction: A comparison and application in a community population. Respirology. 2024. doi:10.1111/resp.14754
BibTeX
@article{Hui2024,
author = {Hui, Xinjie and Cao, Wenhao and Xu, Zeyu and Guo, Junwei and Luo, Jinmei and Xiao, Yi},
title = {Hypoxic indices for obstructive sleep apnoea severity and cardiovascular disease risk prediction: A comparison and application in a community population},
journal = {Respirology},
year = {2024},
doi = {10.1111/resp.14754}
}
EUVIMED